July 16, 2019

TreatmentTrends®: Multiple Sclerosis – A Comprehensive Report on MS Treatment



What if you could really know what was going on in your doctor’s head regarding your specific illness?  What if you could find out what medications he or she really supported for your treatment and which ones he or she had reservations about?  What if you could compare your treatment options with those of your peers who live with the same condition?  Well, now you can have all of those answers at your fingertips without having to grill your doctor. BioTrends, a market research firm, has compiled responses from approximately one hundred neurologists about treatment options for multiple sclerosis, including pros and cons, patients who respond best and worst, and whether they expect to use particular products in the future.  They also answered questions about certain products that are in the research stages and discussed which ones they believe have the most promise.  This new report, detailing the neurologists’ answers, is called Treatment Trends: Multiple Sclerosis.

The neurologists confirmed that they are most likely to prescribe the drug Tysabri, among all other medications on the market.  This confirmation also indicated that there had actually been an increase in the prescription of this particular drug.  The doctors did report, however, that they are still hesitant about using Tysabri or expanding its use due to concerns that taking the drug may lead to the development of Progressive Multifocal Leukoncephalopathy, which is a disabling and deadly disease caused by a virus.  They also noted that because of the risks associated with Tysabri, the neurologists often encourage their patients to take a break from using the drug.

Additionally, the report notes that approximately one-third of the neurologists have prescribed the new drug Ampyra, which is used to help multiple sclerosis patients walk better.  What’s more is that about half of those not currently using the drug expect to within the next six months.  The neurologists were also excited about using the highly anticipated oral medications, including Gilenia.  In fact, they remarked that this area was in the greatest need of development for the disease.  They also want to see medications and therapies that actually reduce the progression of the disease.

Reading a report such as this one by BioTrends can help you to better understand your disease and any medications that you are taking.  It may help you to make informed decisions and have a knowledgeable conversation with your health care provider.  Even though your doc has the medical degree, it is important for you to be an advocate for yourself and ask any questions you may have regarding medication, risks, and what is in development.  Hopefully, this and other reports will help multiple sclerosis sufferers to approach their disability and their doctors with confidence.

About

Jonathan Ginsberg represents disabled men and women in SSDI and SSI claims filed with the Social Security Administration.

Speak Your Mind

*